• Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

© COPYRIGHT 2022. ALL RIGHTS RESERVED.